JP2024061895A - Internal pharmaceutical composition - Google Patents
Internal pharmaceutical composition Download PDFInfo
- Publication number
- JP2024061895A JP2024061895A JP2024043391A JP2024043391A JP2024061895A JP 2024061895 A JP2024061895 A JP 2024061895A JP 2024043391 A JP2024043391 A JP 2024043391A JP 2024043391 A JP2024043391 A JP 2024043391A JP 2024061895 A JP2024061895 A JP 2024061895A
- Authority
- JP
- Japan
- Prior art keywords
- weight
- cinnamon
- nabumetone
- pharmaceutical composition
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 20
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 claims abstract description 44
- 229960004270 nabumetone Drugs 0.000 claims abstract description 43
- 230000000202 analgesic effect Effects 0.000 claims abstract description 32
- 241000723347 Cinnamomum Species 0.000 claims abstract description 27
- 235000017803 cinnamon Nutrition 0.000 claims abstract description 26
- 235000020230 cinnamon extract Nutrition 0.000 claims abstract description 21
- 239000008203 oral pharmaceutical composition Substances 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims description 14
- 230000002708 enhancing effect Effects 0.000 claims description 9
- 241000411851 herbal medicine Species 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 3
- GDVKFRBCXAPAQJ-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O GDVKFRBCXAPAQJ-UHFFFAOYSA-A 0.000 abstract description 19
- 229960001545 hydrotalcite Drugs 0.000 abstract description 19
- 229910001701 hydrotalcite Inorganic materials 0.000 abstract description 19
- AMZWNNKNOQSBOP-UHFFFAOYSA-M [n'-(2,5-dioxoimidazolidin-4-yl)carbamimidoyl]oxyaluminum;dihydrate Chemical compound O.O.NC(=O)NC1N=C(O[Al])NC1=O AMZWNNKNOQSBOP-UHFFFAOYSA-M 0.000 abstract description 18
- 229940015825 aldioxa Drugs 0.000 abstract description 18
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 abstract description 18
- 239000001095 magnesium carbonate Substances 0.000 abstract description 18
- 229910000021 magnesium carbonate Inorganic materials 0.000 abstract description 18
- 229960001708 magnesium carbonate Drugs 0.000 abstract description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 239000004615 ingredient Substances 0.000 description 17
- 239000000284 extract Substances 0.000 description 11
- 239000002552 dosage form Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 235000008499 Canella winterana Nutrition 0.000 description 8
- 244000080208 Canella winterana Species 0.000 description 8
- 229940017545 cinnamon bark Drugs 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 229960001193 diclofenac sodium Drugs 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012676 herbal extract Substances 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 150000002484 inorganic compounds Chemical class 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- LOWWSYWGAKCKLG-UHFFFAOYSA-N 2-(6-methoxynaphthalen-1-yl)acetic acid Chemical compound OC(=O)CC1=CC=CC2=CC(OC)=CC=C21 LOWWSYWGAKCKLG-UHFFFAOYSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 108010037464 Cyclooxygenase 1 Proteins 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 206010014020 Ear pain Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000218195 Lauraceae Species 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 230000006750 UV protection Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical class CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940124568 digestive agent Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 208000007176 earache Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- -1 flavorings Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000000321 herbal drug Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- WORCCYVLMMTGFR-UHFFFAOYSA-M loxoprofen sodium Chemical compound [Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 WORCCYVLMMTGFR-UHFFFAOYSA-M 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 239000011251 protective drug Substances 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
【課題】本発明の目的は、ナブメトンの鎮痛作用を増強させた内服用医薬組成物を提供することである。【解決手段】内服用医薬組成物において、ナブメトンと共に、合成ヒドロタルサイト、炭酸マグネシウム、アルジオキサ、ケイヒ、及び／又はケイヒエキスを組み合わせて使用すると、ナブメトンの鎮痛作用が飛躍的に増強し得る。【選択図】なし[Problem] The object of the present invention is to provide an oral pharmaceutical composition that enhances the analgesic effect of nabumetone. [Solution] When nabumetone is used in combination with synthetic hydrotalcite, magnesium carbonate, aldioxa, cinnamon, and/or cinnamon extract in an oral pharmaceutical composition, the analgesic effect of nabumetone can be dramatically enhanced. [Selected Figure] None
Description
本発明は、ナブメトンを含む内服用医薬組成物に関する。より詳細には、本発明は、ナブメトンの鎮痛作用が増強している内服用医薬組成物に関する。 The present invention relates to an oral pharmaceutical composition containing nabumetone. More specifically, the present invention relates to an oral pharmaceutical composition in which the analgesic effect of nabumetone is enhanced.
ナブメトン、ジクロフェナクナトリウム、イブプロフェン、ロキソプロフェンナトリウム等の非ステロイド性抗炎症剤は、ステロイド性抗炎症剤で見られるような重篤な副作用の懸念が少なく、使用量や使用期間等の制約も少ないため、鎮痛、解熱、消炎等を目的とした内服用医薬組成物において汎用されている。非ステロイド性抗炎症剤の内、ナブメトンは、肝臓で代謝されて活性体である6-メトキシ-2-ナフチル酢酸に変換され、当該活性化体がシクロオキシゲナーゼ１よりもシクロオキシゲナーゼ２に対する阻害作用が高い非ステロイド性抗炎症剤である。非ステロイド性抗炎症剤の中でも、ナブメトンは、服用回数が少なく、更に副作用が比較的少ないことが知られている。 Non-steroidal anti-inflammatory agents such as nabumetone, diclofenac sodium, ibuprofen, and loxoprofen sodium are less likely to cause serious side effects as seen with steroidal anti-inflammatory agents, and there are fewer restrictions on the dosage and duration of use, so they are widely used in oral pharmaceutical compositions for the purposes of analgesia, antipyresis, anti-inflammation, etc. Among non-steroidal anti-inflammatory agents, nabumetone is metabolized in the liver and converted to the active form 6-methoxy-2-naphthylacetic acid, and this activated form is a non-steroidal anti-inflammatory agent that has a stronger inhibitory effect on cyclooxygenase 2 than on cyclooxygenase 1. Among non-steroidal anti-inflammatory agents, nabumetone is known to be taken less frequently and to have relatively few side effects.
従来、ステロイド性抗炎症剤の鎮痛作用を増強した製剤処方について種々検討が行われている。例えば、特許文献１には、ナブメトン、ジクロフェナク等のフェニル酢酸誘導体又は塩と、メントール類を併用することによって、消炎鎮痛作用が増強することが開示されている。また、特許文献２には、イブプロフェン等のプロピオン酸系鎮痛剤と２種以上のビタミンＢ類を併用することによって、鎮痛作用が増強することが開示されているが、ナブメトンを含む製剤については具体的に検討されていない。 Various studies have been conducted on pharmaceutical formulations that enhance the analgesic effect of steroidal anti-inflammatory agents. For example, Patent Document 1 discloses that the anti-inflammatory and analgesic effects are enhanced by combining a phenylacetic acid derivative or salt such as nabumetone or diclofenac with a menthol. Patent Document 2 discloses that the analgesic effect is enhanced by combining a propionic acid analgesic such as ibuprofen with two or more types of B vitamins, but no specific studies have been conducted on formulations containing nabumetone.
近年、医薬分野において薬効の増強に対する要望が高まっており、新たな製剤技術により、ナブメトンの鎮痛作用を増強させる技術の開発が求められている。そこで、本発明は、ナブメトンの鎮痛作用を増強させた内服用医薬組成物を提供することを目的とする。 In recent years, there has been an increasing demand in the pharmaceutical field for enhanced efficacy, and there is a need to develop a technology to enhance the analgesic effect of nabumetone using new formulation technology. Therefore, the present invention aims to provide an oral pharmaceutical composition that enhances the analgesic effect of nabumetone.
本発明者は、前記課題を解決すべく鋭意検討を行ったところ、内服用医薬組成物において、ナブメトンと共に、合成ヒドロタルサイト、炭酸マグネシウム、アルジオキサ、ケイヒ、及び／又はケイヒエキスを組み合わせて使用すると、ナブメトンの鎮痛作用が飛躍的に増強し得ることを見出した。本発明は、かかる知見に基づいて、更に検討を重ねることにより完成したものである。 The inventors have conducted extensive research to solve the above problems and have found that the analgesic effect of nabumetone can be dramatically enhanced by combining synthetic hydrotalcite, magnesium carbonate, aldioxa, cinnamon, and/or cinnamon extract with nabumetone in an oral pharmaceutical composition. The present invention was completed based on this finding and through further research.
即ち、本発明は、下記に掲げる態様の発明を提供する。
項１． (A)ナブメトン、並びに(B)合成ヒドロタルサイト、炭酸マグネシウム、アルジオキサ、ケイヒ、及びケイヒエキスよりなる群から選択される少なくとも１種を含有する、内服用医薬組成物。
項２． 前記(A)成分１００重量部当たり、前記(B)成分を総量（但し、(B)成分がケイヒ、及びケイヒエキスの場合は原生薬換算量）で０．１～６０００重量部含む、項１に記載の内服用医薬組成物。
項３． 前記(B)成分が、合成ヒドロタルサイトである、項１又は２に記載の内服用医薬組成物。
項４． 鎮痛用途に使用される、項１～３のいずれかに記載の内服用医薬組成物。
項５． ナブメトンの鎮痛作用を増強する方法であって、
内服用医薬組成物に、ナブメトンと共に、合成ヒドロタルサイト、炭酸マグネシウム、アルジオキサ、ケイヒ、及びケイヒエキスよりなる群から選択される少なくとも１種を配合する、鎮痛作用増強方法。
That is, the present invention provides the following aspects.
Item 1. A pharmaceutical composition for internal use, comprising (A) nabumetone and (B) at least one member selected from the group consisting of synthetic hydrotalcite, magnesium carbonate, aldioxa, cinnamon, and cinnamon extract.
Item 2. The pharmaceutical composition for internal use according to Item 1, comprising 0.1 to 6,000 parts by weight of the total amount of the component (B) (when the component (B) is cinnamon or cinnamon extract, the amount is calculated as the crude drug) per 100 parts by weight of the component (A).
Item 3. The pharmaceutical composition for internal use according to Item 1 or 2, wherein the component (B) is synthetic hydrotalcite.
Item 4. The pharmaceutical composition for internal use according to any one of Items 1 to 3, which is used for analgesic purposes.
Item 5. A method for enhancing the analgesic effect of nabumetone, comprising the steps of:
A method for enhancing analgesic effect, comprising blending nabumetone together with at least one member selected from the group consisting of synthetic hydrotalcite, magnesium carbonate, aldioxa, cinnamon, and cinnamon extract in an oral pharmaceutical composition.
本発明の内服用医薬組成物によれば、ナブメトンと、合成ヒドロタルサイト、炭酸マグネシウム、アルジオキサ、ケイヒ、及び／又はケイヒエキスとを併用することによって、ナブメトンの鎮痛作用を飛躍的に増強させることができる。 According to the oral pharmaceutical composition of the present invention, the analgesic effect of nabumetone can be dramatically enhanced by combining nabumetone with synthetic hydrotalcite, magnesium carbonate, aldioxa, cinnamon, and/or cinnamon extract.
１．内服用医薬組成物
本発明の内服用医薬組成物は、ナブメトン（以下、「(A)成分」と表記することもある）と、合成ヒドロタルサイト、炭酸マグネシウム、アルジオキサ、ケイヒ、及びケイヒエキスよりなる群から選択される少なくとも１種（以下、「(B)成分」と表記することもある）を含有することを特徴とする。以下、本発明の内服用医薬組成物について詳述する。
1. Oral Pharmaceutical Composition The oral pharmaceutical composition of the present invention is characterized by containing nabumetone (hereinafter, also referred to as "ingredient (A)") and at least one selected from the group consisting of synthetic hydrotalcite, magnesium carbonate, aldioxa, cinnamon, and cinnamon extract (hereinafter, also referred to as "ingredient (B)"). The oral pharmaceutical composition of the present invention will be described in detail below.
［(A)成分］
本発明の内服用医薬組成物は、鎮痛成分として、ナブメトンを含有する。ナブメトンとは、４－（６－メトキシナフタレン－２－イル）－２－ブタノンとも称される公知の非ステロイド性抗炎症剤である。
[Component (A)]
The internal pharmaceutical composition of the present invention contains nabumetone as an analgesic ingredient. Nabumetone is a known nonsteroidal anti-inflammatory agent also known as 4-(6-methoxynaphthalen-2-yl)-2-butanone.
本発明の内服用医薬組成物における(A)成分の含有量については、剤型、投与量等に応じて適宜設定すればよいが、例えば、１～９０重量％、好ましくは５～８０重量％が挙げられる。 The content of component (A) in the internal pharmaceutical composition of the present invention may be appropriately set depending on the dosage form, dosage amount, etc., but may be, for example, 1 to 90% by weight, preferably 5 to 80% by weight.
［(B)成分］
本発明の内服用医薬組成物は、ナブメトンの鎮痛作用を増強させる成分として、合成ヒドロタルサイト、炭酸マグネシウム、アルジオキサ、ケイヒ、及びケイヒエキスよりなる群から選択される少なくとも１種を含有する。これらの(B)成分をナブメトンと併用することによって、ナブメトンの鎮痛作用を飛躍的に増強させることができる。
[Component (B)]
The pharmaceutical composition for internal use of the present invention contains at least one component selected from the group consisting of synthetic hydrotalcite, magnesium carbonate, aldioxa, cinnamon, and cinnamon extract as an ingredient for enhancing the analgesic effect of nabumetone. By using the component (B) in combination with nabumetone, the analgesic effect of nabumetone can be dramatically enhanced.
(B)成分の内、合成ヒドロタルサイト及び炭酸マグネシウムは、医薬分野において、制酸剤等として使用されている公知の無機化合物である。 Of the (B) components, synthetic hydrotalcite and magnesium carbonate are well-known inorganic compounds used in the pharmaceutical field as antacids, etc.
(B)成分の内、アルジオキサは、医薬分野において、胃粘膜保護薬等として使用されている公知の無機化合物である。 Of the (B) components, aldioxa is a known inorganic compound used in the pharmaceutical field as a gastric mucosa protective drug, etc.
(B)成分の内、ケイヒは、クスノキ科トンキンニッケイやその他同属植物の樹皮を乾燥したものであり、生薬として使用されている公知の成分である。本発明に使用されるケイヒは、粉砕物、細切物、粉末物、及びこれらの乾燥物のいずれであってもよいが、好ましくは粉末物（ケイヒ末）が挙げられる。 Of the (B) components, cinnamon is the dried bark of Cinnamomum moniliforme (Cinnamon) and other plants of the same genus, which belong to the Lauraceae family, and is a well-known ingredient used as a herbal medicine. The cinnamon used in the present invention may be in the form of crushed material, shredded material, powder, or any of these dried products, but is preferably in the form of powder (cinnamon powder).
(B)成分の内、ケイヒエキスは、ケイヒを抽出原料として抽出処理することにより得られる抽出物であり、公知の手法で抽出処理することにより得ることができる。ケイヒエキスの抽出処理に使用される抽出溶媒としては、例えば、水(熱水含む)；エタノール等の低級アルコール；１，３－ブチレングリコール等の多価アルコール；これらの混合液等の極性溶媒が挙げられ、好ましくは水、エタノール、１，３－ブチレングリコール、又はこれらの混合溶媒である。ケイヒエキスの製造において採用される抽出方法については、特に制限されず、生薬エキスの製造に使用される一般的な抽出手法であればよい。例えば抽出溶媒中に原生薬を冷浸、温浸等によって浸漬し、必要に応じて撹拌する方法；パーコレーション法；水蒸気蒸留法等を挙げることができる。得られた抽出液を、必要に応じてろ過または遠心分離によって固形物を除去することにより、生薬エキスを回収できる。ケイヒエキスは、上記抽出処理により得られた液状のエキスをそのまま使用してもよいが、必要に応じて、一部又は全ての溶媒を除去して濃縮液（軟エキス）若しくは乾燥物（乾燥エキス）として使用してもよい。また、これらの濃縮液（軟エキス）若しくは乾燥物（乾燥エキス）を更に精製処理に供してもよく、更にこれらを適当な溶剤に溶解若しくは懸濁して用いることもできる。 Among the (B) components, cinnamon extract is an extract obtained by extracting cinnamon as an extraction raw material, and can be obtained by extracting it by a known method. Examples of the extraction solvent used in the extraction process of cinnamon extract include polar solvents such as water (including hot water); lower alcohols such as ethanol; polyhydric alcohols such as 1,3-butylene glycol; and mixtures of these, and preferably water, ethanol, 1,3-butylene glycol, or a mixture of these. The extraction method used in the production of cinnamon extract is not particularly limited, and may be a general extraction method used in the production of herbal extracts. For example, a method in which the raw herbal medicine is immersed in the extraction solvent by cold immersion, hot immersion, etc., and stirred as necessary; a percolation method; a steam distillation method, etc. can be mentioned. The obtained extract can be filtered or centrifuged to remove solids as necessary to recover the herbal extract. The liquid extract obtained by the above extraction process may be used as it is, but if necessary, a part or all of the solvent may be removed and the cinnamon extract may be used as a concentrated liquid (soft extract) or a dried product (dry extract). In addition, these concentrated liquids (soft extracts) or dried products (dry extracts) may be subjected to further purification treatment, and they may also be dissolved or suspended in an appropriate solvent for use.
これらの(B)成分は、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。 These (B) components may be used alone or in combination of two or more.
また、本発明の内服用医薬組成物において、(A)成分と(B)成分の比率としては、例えば、(A)成分１００重量部当たり、(B)成分の総量が０．１～６０００重量部が挙げられる。なお、前記比率は、(B)成分がケイヒ及び／又はケイヒエキスである場合は、ケイヒ及び／又はケイヒエキスの原生薬換算量に基づいて算出される値である。「原生薬換算量」とは、その成分量を得るために必要な生薬の重量（乾燥重量）である。ケイヒ自体の場合であれば配合するケイヒの重量が原生薬換算量になり、ケイヒエキスの場合であれば、配合されるケイヒエキスの量を得るために必要なケイヒの乾燥重量が原生薬換算量になる。 In the internal pharmaceutical composition of the present invention, the ratio of component (A) to component (B) can be, for example, 0.1 to 6,000 parts by weight of the total amount of component (B) per 100 parts by weight of component (A). When component (B) is cinnamon and/or cinnamon extract, the ratio is a value calculated based on the crude drug equivalent amount of cinnamon and/or cinnamon extract. The "crude drug equivalent amount" is the weight (dry weight) of the crude drug required to obtain the amount of the ingredient. In the case of cinnamon itself, the weight of the cinnamon to be blended is the crude drug equivalent amount, and in the case of cinnamon extract, the dry weight of cinnamon required to obtain the amount of cinnamon extract to be blended is the crude drug equivalent amount.
ナブメトンの鎮痛作用をより一層増強させるという観点から、(B)成分の種類毎の好適な(A)成分と(B)成分の比率は、以下の通りである。
(B)成分が合成ヒドロタルサイトである場合：ナブメトン１００重量部当たり、合成ヒドロタルサイトが、好ましくは０．１～６０００重量部、より好ましくは１～３０００重量部、更に好ましくは１０～１０００重量部。
(B)成分が炭酸マグネシウムである場合：ナブメトン１００重量部当たり、炭酸マグネシウムが、好ましくは０．１～３０００重量部、より好ましくは１～１０００重量部、更に好ましくは１０～５００重量部。
(B)成分がアルジオキサである場合：ナブメトン１００重量部当たり、アルジオキサが、好ましくは０．１～１０００重量部、より好ましくは１～５００重量部、更に好ましくは１～１００重量部。
(B)成分がケイヒ及び／又はケイヒエキスである場合：ナブメトン１００重量部当たり、ケイヒ及び／又はケイヒエキスが、原生薬換算量で、好ましくは０．１～６０００重量部、より好ましくは１～３０００重量部、更に好ましくは３０～１０００重量部。
From the viewpoint of further enhancing the analgesic effect of nabumetone, the preferred ratio of component (A) to component (B) for each type of component (B) is as follows.
When component (B) is synthetic hydrotalcite: the amount of synthetic hydrotalcite is preferably 0.1 to 6000 parts by weight, more preferably 1 to 3000 parts by weight, and even more preferably 10 to 1000 parts by weight per 100 parts by weight of nabumetone.
When component (B) is magnesium carbonate : the amount of magnesium carbonate is preferably 0.1 to 3,000 parts by weight, more preferably 1 to 1,000 parts by weight, and even more preferably 10 to 500 parts by weight, per 100 parts by weight of nabumetone.
When component (B) is aldioxa : the amount of aldioxa is preferably 0.1 to 1,000 parts by weight, more preferably 1 to 500 parts by weight, and even more preferably 1 to 100 parts by weight, per 100 parts by weight of nabumetone.
(B) When the component is cinnamon and/or cinnamon extract : the amount of cinnamon and/or cinnamon extract, calculated as the raw herbal drug, per 100 parts by weight of nabumetone is preferably 0.1 to 6,000 parts by weight, more preferably 1 to 3,000 parts by weight, and even more preferably 30 to 1,000 parts by weight.
本発明の内服用医薬組成物における(B)成分の含有量については、前述する(A)成分と(B)成分の比率に応じた範囲内で、使用する(B)成分の種類、剤型、投与量等に応じて適宜設定すればよいが、例えば、０．１～９５重量％が挙げられる。 The content of component (B) in the oral pharmaceutical composition of the present invention may be set appropriately according to the type, dosage form, and dosage of component (B) used within the range corresponding to the ratio of components (A) and (B) described above, and may be, for example, 0.1 to 95% by weight.
(B)成分の種類毎の好適な(A)成分と(B)成分の含有量は、以下の通りである。
(B)成分が合成ヒドロタルサイトである場合：(A)成分が５～９９重量％且つ合成ヒドロタルサイトが１～９５重量％、好ましくは(A)成分が１０～５０重量％且つ合成ヒドロタルサイトが５０～９０重量％、より好ましくは(A)成分が１５～３０重量％且つ合成ヒドロタルサイトが７０～８５重量％。
(B)成分が炭酸マグネシウムである場合：(A)成分が５～９９重量％且つ炭酸マグネシウムが１～９５重量％、好ましくは(A)成分が２０～７０重量％且つ炭酸マグネシウムが３０～８０重量％、より好ましくは(A)成分が２５～３５重量％且つ炭酸マグネシウムが６５～７５重量％。
(B)成分がアルジオキサである場合：(A)成分が５～９９重量％且つアルジオキサが１～９５重量％、好ましくは(A)成分が５０～９５重量％且つアルジオキサが５～５０重量％、より好ましくは(A)成分が６０～７０重量％且つアルジオキサが３０～４０重量％。
(B)成分がケイヒ及び／又はケイヒエキスである場合：(A)成分が５～９５重量％且つケイヒ及び／又はケイヒエキスが原生薬換算量で５～９５重量％、好ましくは(A)成分が１３～６５重量％且つケイヒ及び／又はケイヒエキスが原生薬換算量で３５～８７重量％、より好ましくは(A)成分が１０～２０重量％且つケイヒ及び／又はケイヒエキスが原生薬換算量で８０～９０重量％。
The preferred contents of components (A) and (B) for each type of component (B) are as follows:
When component (B) is synthetic hydrotalcite : 5 to 99% by weight of component (A) and 1 to 95% by weight of synthetic hydrotalcite, preferably 10 to 50% by weight of component (A) and 50 to 90% by weight of synthetic hydrotalcite, and more preferably 15 to 30% by weight of component (A) and 70 to 85% by weight of synthetic hydrotalcite.
When component (B) is magnesium carbonate : 5 to 99 weight % of component (A) and 1 to 95 weight % of magnesium carbonate, preferably 20 to 70 weight % of component (A) and 30 to 80 weight % of magnesium carbonate, more preferably 25 to 35 weight % of component (A) and 65 to 75 weight % of magnesium carbonate.
When component (B) is aldioxa : 5 to 99% by weight of component (A) and 1 to 95% by weight of aldioxa, preferably 50 to 95% by weight of component (A) and 5 to 50% by weight of aldioxa, more preferably 60 to 70% by weight of component (A) and 30 to 40% by weight of aldioxa.
When the (B) component is cinnamon bark and/or cinnamon bark extract : the (A) component is 5 to 95 weight % and the cinnamon bark and/or cinnamon bark extract is 5 to 95 weight % in terms of the raw drug amount, preferably the (A) component is 13 to 65 weight % and the cinnamon bark and/or cinnamon bark extract is 35 to 87 weight % in terms of the raw drug amount, and more preferably the (A) component is 10 to 20 weight % and the cinnamon bark and/or cinnamon bark extract is 80 to 90 weight % in terms of the raw drug amount.
［その他の含有成分］
本発明の内服用医薬組成物には、前述する成分以外に、必要に応じて、他の薬理成分を含んでいてもよい。このような薬理成分の種類については、特に制限されないが、例えば、ビタミン類、ナブメトン以外の消炎鎮痛剤、腸管運動改善剤、消化剤、鎮痙剤、粘膜修復剤、収れん剤、鎮吐剤、鎮咳剤、去痰剤、消炎酵素剤、鎮静催眠剤、抗ヒスタミン剤、強心利尿剤、抗菌剤、血管収縮剤、血管拡張剤、局所麻酔剤、プロトンポンプ阻害薬、生薬、生薬エキス、カフェイン類、メントール類、ポリフェノール等が挙げられる。これらの薬理成分は、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。また、これらの薬理成分の含有量については、使用する薬理成分の種類や内服用医薬組成物の剤型等に応じて適宜設定すればよい。
[Other ingredients]
The internal pharmaceutical composition of the present invention may contain other pharmacological ingredients, if necessary, in addition to the above-mentioned ingredients. The types of such pharmacological ingredients are not particularly limited, and examples thereof include vitamins, anti-inflammatory analgesics other than nabumetone, intestinal motility improving agents, digestive agents, antispasmodics, mucosal repair agents, astringents, antiemetics, antitussives, expectorants, anti-inflammatory enzymes, sedatives, hypnotics, antihistamines, cardiac diuretics, antibacterial agents, vasoconstrictors, vasodilators, local anesthetics, proton pump inhibitors, herbal medicines, herbal extracts, caffeines, menthols, polyphenols, etc. These pharmacological ingredients may be used alone or in combination of two or more kinds. The content of these pharmacological ingredients may be appropriately set depending on the type of pharmacological ingredient used and the dosage form of the internal pharmaceutical composition.
本発明の医薬組成物には、所望の剤型に調製するために、必要に応じて、薬学的に許容される基剤や添加剤等が含まれていてもよい。このような基剤及び添加剤としては、例えば、賦形剤、結合剤、崩壊剤、滑沢剤、等張化剤、可塑剤、分散剤、乳化剤、溶解補助剤、湿潤化剤、安定化剤、懸濁化剤、粘着剤、コーティング剤、光沢化剤、水、油脂類、ロウ類、炭化水素類、脂肪酸類、高級アルコール類、エステル類、水溶性高分子、界面活性剤、低級アルコール類、多価アルコール、ｐＨ調整剤、緩衝剤、酸化防止剤、紫外線防止剤、防腐剤、矯味剤、香料、粉体、増粘剤、色素、キレート剤等が挙げられる。これらの基剤や添加剤は、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。また、これらの基剤や添加剤の含有量については、使用する添加成分の種類や内服用医薬組成物の剤型等に応じて適宜設定すればよい。 The pharmaceutical composition of the present invention may contain pharma- ceutically acceptable bases and additives, etc., as necessary, in order to prepare the pharmaceutical composition into a desired dosage form. Examples of such bases and additives include excipients, binders, disintegrants, lubricants, isotonicity agents, plasticizers, dispersants, emulsifiers, solubilizers, wetting agents, stabilizers, suspending agents, adhesives, coating agents, glossing agents, water, oils and fats, waxes, hydrocarbons, fatty acids, higher alcohols, esters, water-soluble polymers, surfactants, lower alcohols, polyhydric alcohols, pH adjusters, buffers, antioxidants, UV protection agents, preservatives, flavorings, fragrances, powders, thickeners, dyes, chelating agents, etc. These bases and additives may be used alone or in combination of two or more. The content of these bases and additives may be appropriately set according to the type of additive used and the dosage form of the pharmaceutical composition for internal use.
［剤型］
本発明の内服用医薬組成物の剤型については、特に制限されず、固体状製剤、半固体状製剤、又は液体状製剤のいずれであってもよい。
[Dosage form]
The dosage form of the internal pharmaceutical composition of the present invention is not particularly limited, and may be any of a solid preparation, a semi-solid preparation, or a liquid preparation.
固体状製剤としては、具体的には、錠剤、丸剤、カプセル剤（軟カプセル剤、硬カプセル剤）、散剤、顆粒剤（ドライシロップを含む）等が挙げられる。半固体状製剤としては、具体的には、ゼリー剤等が挙げられる。液体状製剤としては、具体的には、液剤、懸濁剤、シロップ剤等が挙げられる。 Specific examples of solid preparations include tablets, pills, capsules (soft capsules, hard capsules), powders, and granules (including dry syrups).Specific examples of semi-solid preparations include jellies.Specific examples of liquid preparations include solutions, suspensions, and syrups.
これらの剤型の中でも、好ましくは固体状製剤が挙げられる。 Among these dosage forms, solid formulations are preferred.
本発明の内服用医薬組成物を前記剤型に調製するには、(A)成分、(B)成分、及び必要に応じて添加される他の薬理成分、基剤、及び添加剤を用いて、医薬分野で採用されている通常の製剤化手法に従って製剤化すればよい。 To prepare the oral pharmaceutical composition of the present invention in the above dosage form, the composition may be formulated according to the usual formulation methods used in the pharmaceutical field using component (A), component (B), and other pharmacological ingredients, bases, and additives that are added as necessary.
［用法・用量］
本発明の内服用医薬組成物は、鎮痛作用が増強しており、優れた鎮痛効果を奏し得るので、例えば、頭痛、月経痛（生理痛）・歯痛、抜歯後の疼痛、咽喉痛、腰痛、関節痛、神経痛、筋肉痛、肩こり痛、耳痛、打撲痛、骨折痛、ねんざ痛、外傷痛等の鎮痛；悪寒・発熱時の解熱；感冒症状の緩和等の目的で使用することができる。
[Dosage and Administration]
The internal pharmaceutical composition of the present invention has an enhanced analgesic action and can exert an excellent analgesic effect, and can therefore be used for purposes such as relieving pain from headaches, menstrual pain (period pain), toothache, pain after tooth extraction, sore throat, lower back pain, joint pain, neuralgia, muscle pain, stiff shoulders, earache, bruises, fractures, sprains, and trauma; reducing fever during chills and fever; and alleviating cold symptoms.
本発明の内服用医薬組成物の服用量については、症状の程度、服用者の年齢等に応じて適宜設定すればよいが、例えば、１日当たりのナブメトン服用量が２００～１６００ｍｇ程度、好ましくは４００～１０００ｍｇ程度となる量で、１日当たり１回服用すればよく、年齢、症状によっては複数回に分けて服用してもよい。 The dosage of the oral pharmaceutical composition of the present invention may be appropriately determined depending on the severity of symptoms, the age of the user, etc. For example, the dosage of nabumetone per day is about 200 to 1600 mg, preferably about 400 to 1000 mg, and may be taken once per day, or may be taken in multiple divided doses depending on the user's age and symptoms.
２．鎮痛作用の増強方法
本発明は、更に、ナブメトンの鎮痛作用を増強する方法であって、内服用医薬組成物に、ナブメトンと共に、合成ヒドロタルサイト、炭酸マグネシウム、アルジオキサ、ケイヒ、及びケイヒエキスよりなる群から選択される少なくとも１種を配合することを特徴とする鎮痛作用増強方法を提供する。
2. Method for enhancing analgesic effect The present invention further provides a method for enhancing the analgesic effect of nabumetone, which comprises blending nabumetone together with at least one member selected from the group consisting of synthetic hydrotalcite, magnesium carbonate, aldioxa, cinnamon, and cinnamon extract in an oral pharmaceutical composition.
当該鎮痛作用増強方法において、使用される成分の種類、配合量、内服用医薬組成物の剤型等については、前記「１．内服用医薬組成物」の欄に記載の通りである。 In the method for enhancing analgesic effect, the types of ingredients used, the amounts of ingredients used, the dosage form of the oral pharmaceutical composition, etc. are as described in the above section "1. Oral pharmaceutical composition."
以下、本発明を実施例により具体的に説明するが、本発明はこれらの実施例に限定されるものではない。 The present invention will be described in detail below with reference to examples, but the present invention is not limited to these examples.
試験例１：鎮痛作用の評価試験
６週齢の雄性マウス（Ｓｌｃ：ｄｄｙ、日本エスエルシー株式会社）をコントロール群及び試験群（実施例１～４及び比較例１）の６群（１群当たり７～１１匹）に分けた。各群のマウスを１週間飼育して馴化させた後に以下の条件で試験を行った。
Test Example 1: Evaluation test of analgesic effect Six-week-old male mice (Slc:ddy, Japan SLC Co., Ltd.) were divided into 6 groups (7-11 mice per group) of control group and test groups (Examples 1-4 and Comparative Example 1). Each group of mice was kept for 1 week for acclimatization, and then the test was carried out under the following conditions.
・コントロール群
約１６時間絶食させた後に、０．１重量％のカルボキシメチルセルロースを含有する水溶液（コントロール液）を１０ｍｌ／ｋｇ（マウス体重）となるように経口投与した。コントロール液の投与から５０分後に、０．６重量％酢酸水溶液を２０ｍｌ／ｋｇ（マウス体重）となるように腹腔内投与した。酢酸水溶液投与の１０分経過後からの１０分間のマウスのライジング行動（後肢を伸ばす運動）の回数を計測した。
Control group: After fasting for about 16 hours, an aqueous solution containing 0.1% by weight of carboxymethylcellulose (control solution) was orally administered at 10 ml/kg (mouse body weight). 50 minutes after administration of the control solution, an aqueous solution of 0.6% by weight of acetic acid was intraperitoneally administered at 20 ml/kg (mouse body weight). The number of times the mouse writhed (stretched hind legs) occurred for 10 minutes starting from 10 minutes after administration of the aqueous solution of acetic acid was counted.
・試験群
約１６時間絶食させた後に、表１に示す成分を所定の投与量となるように前記コントロール液に添加した試験液を１０ｍｌ／ｋｇ（マウス体重）となるように経口投与した。試験液の投与から５０分後に、０．６重量％酢酸水溶液を２０ｍｌ／ｋｇ（マウス体重）となるように腹腔内投与した。酢酸水溶液投与の１０分経過後からの１０分間のマウスのライジング行動（後肢を伸ばす運動）の回数を計測した。
After fasting for about 16 hours, the test group was orally administered a test solution containing the control solution to which the components shown in Table 1 had been added in the prescribed dose at 10 ml/kg (mouse body weight). 50 minutes after administration of the test solution, a 0.6 wt% aqueous acetic acid solution was intraperitoneally administered at 20 ml/kg (mouse body weight). The number of times the mouse writhed (stretched hind limbs) occurred was counted for 10 minutes starting 10 minutes after administration of the aqueous acetic acid solution.
結果を図１に示す。この結果、ナブメトンと、炭酸マグネシウム、アルジオキサ、合成ヒドロタルサイト、又はケイヒ末とを併用した場合（実施例１～４）では、ナブメトン単独の場合（比較例１）に比べて、ライジング行動の回数が有意に減っており、ナブメトンの鎮痛作用が顕著に増強していることが確認された。 The results are shown in Figure 1. As a result, when nabumetone was used in combination with magnesium carbonate, aldioxa, synthetic hydrotalcite, or cinnamon powder (Examples 1 to 4), the number of writhing behaviors was significantly reduced compared to when nabumetone was used alone (Comparative Example 1), confirming that the analgesic effect of nabumetone was significantly enhanced.
参考試験例１：鎮痛作用の評価試験
試験群として、表２に示す成分を所定の投与量となるように投与したこと以外は、前記試験例１と同様の方法で試験を行い、ライジング行動の回数を求めた。ジクロフェナクナトリウムは、ナブメトンと同じフェニル酢酸系非ステロイド抗炎症剤である。
Reference Test Example 1: Evaluation test of analgesic effect The test was conducted in the same manner as in Test Example 1, except that the test groups were administered the components shown in Table 2 in the prescribed doses, and the number of writhing behaviors was calculated. Diclofenac sodium is a phenylacetic acid-based nonsteroidal anti-inflammatory drug, the same as nabumetone.
結果を図２に示す。この結果、ジクロフェナクナトリウムと、炭酸マグネシウム、アルジオキサ、合成ヒドロタルサイト、又はケイヒ末を併用した場合（参考例２～５）では、ジクロフェナクナトリウム単独の場合（参考例１）に比べて、ライジング行動の回数が同等又は多くなる傾向が認められた。即ち、本試験結果から、ジクロフェナクナトリウムと、炭酸マグネシウム、アルジオキサ、合成ヒドロタルサイト、又はケイヒ末を使用することによる鎮痛作用の増強は、非ステロイド性抗炎症剤としてナブメトンを選択した場合に認められる特有の効果であることが確認された。 The results are shown in Figure 2. As a result, when diclofenac sodium was used in combination with magnesium carbonate, aldioxa, synthetic hydrotalcite, or cinnamon powder (Reference Examples 2 to 5), the number of writhing behaviors tended to be equal or greater than when diclofenac sodium was used alone (Reference Example 1). In other words, the test results confirmed that the enhanced analgesic effect achieved by using diclofenac sodium in combination with magnesium carbonate, aldioxa, synthetic hydrotalcite, or cinnamon powder is a unique effect observed when nabumetone is selected as the nonsteroidal anti-inflammatory agent.
製剤例
表３～５に示す組成の錠剤を調製した。表３～５において各含有成分の含有量の単位は、１日当たりの服用量（ｍｇ）である。これらの錠剤は、ナブメトンの鎮痛作用の飛躍的な向上が期待できる。
Tablets having the compositions shown in Formulation Examples Tables 3 to 5 were prepared. The units of the content of each ingredient in Tables 3 to 5 are the daily dose (mg). These tablets are expected to dramatically improve the analgesic effect of nabumetone.
Claims (4)
内服用医薬組成物に、ナブメトンと共に、ケイヒ、及びケイヒエキスよりなる群から選択される少なくとも１種を配合する、鎮痛作用増強方法。 1. A method for enhancing the analgesic effect of nabumetone, comprising:
A method for enhancing analgesic effect, comprising blending at least one member selected from the group consisting of cinnamon and cinnamon extract together with nabumetone in an oral pharmaceutical composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024043391A JP2024061895A (en) | 2019-12-27 | 2024-03-19 | Internal pharmaceutical composition |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019238435A JP2021107330A (en) | 2019-12-27 | 2019-12-27 | Oral pharmaceutical composition |
| JP2024043391A JP2024061895A (en) | 2019-12-27 | 2024-03-19 | Internal pharmaceutical composition |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019238435A Division JP2021107330A (en) | 2019-12-27 | 2019-12-27 | Oral pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2024061895A true JP2024061895A (en) | 2024-05-08 |
Family
ID=76967645
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019238435A Pending JP2021107330A (en) | 2019-12-27 | 2019-12-27 | Oral pharmaceutical composition |
| JP2024043392A Pending JP2024061896A (en) | 2019-12-27 | 2024-03-19 | Internal pharmaceutical composition |
| JP2024043391A Pending JP2024061895A (en) | 2019-12-27 | 2024-03-19 | Internal pharmaceutical composition |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019238435A Pending JP2021107330A (en) | 2019-12-27 | 2019-12-27 | Oral pharmaceutical composition |
| JP2024043392A Pending JP2024061896A (en) | 2019-12-27 | 2024-03-19 | Internal pharmaceutical composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (3) | JP2021107330A (en) |
-
2019
- 2019-12-27 JP JP2019238435A patent/JP2021107330A/en active Pending
-
2024
- 2024-03-19 JP JP2024043392A patent/JP2024061896A/en active Pending
- 2024-03-19 JP JP2024043391A patent/JP2024061895A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024061896A (en) | 2024-05-08 |
| JP2021107330A (en) | 2021-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2017066474A1 (en) | Compositions and methods for pain relief | |
| EP2379092B1 (en) | Compositions comprising a lipophilic extract of zingiber officinale and an extract of cynara scolymus | |
| JP2006513204A (en) | Development of antitussive, antitussive and throat sedative herbal preparations | |
| Brendler et al. | Devil’s Claw (Harpagophytum procumbens DC) an evidence-based systematic review by the natural standard research collaboration | |
| JP2024061895A (en) | Internal pharmaceutical composition | |
| JP2007291071A (en) | Hypnotic pharmaceutical composition | |
| JP6935285B2 (en) | Pharmaceutical composition | |
| JP7229012B2 (en) | Pharmaceutical composition for internal use | |
| JP7229013B2 (en) | Pharmaceutical composition for internal use | |
| JP6940265B2 (en) | Antidiarrheal composition | |
| JP6940264B2 (en) | Antidiarrheal composition | |
| JP2020002087A (en) | Pharmaceutical composition for internal use | |
| JP2024055991A (en) | Internal pharmaceutical composition | |
| KR20170043484A (en) | Pharmaceutical composition for treating or improving arthritis comprising high amount of an active ingredient derived from herbal substances | |
| JP7170437B2 (en) | Pharmaceutical composition for internal use | |
| JP7068803B2 (en) | Pharmaceutical composition for reducing blood lipids | |
| JPH06107553A (en) | Composition having analgesic function | |
| US11890312B2 (en) | Composition comprising herbal extracts | |
| JP7493936B2 (en) | Fibrosis inhibitors | |
| JP6949645B2 (en) | Pharmaceutical composition | |
| JP2024015395A (en) | Hydragogue agent | |
| JP6938315B2 (en) | tablet | |
| JP6676326B2 (en) | Chinese herbal preparations for antidiarrheal | |
| JP2024015394A (en) | Obesity improving agent | |
| KR101488688B1 (en) | Pharmaceutical composition for treating or improving arthritis comprising aceclofenac or pharmaceutically acceptable salt thereof, and extract of clematis mandshurica, trichosanthes kirilowii and prunella vulgaris |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240415 |